UBS Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $64
Portfolio Pulse from richadhand@benzinga.com
UBS analyst Eliana Merle maintains a Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) and raises the price target from $60 to $64.
August 23, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS maintains a Buy rating on Apellis Pharmaceuticals and raises the price target from $60 to $64, which could lead to a positive impact on the stock.
The raised price target by UBS indicates a positive outlook for Apellis Pharmaceuticals. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100